myasthenia gravis association
MGA
of the heartland

STRENGTH AND
CONNECTIONS
HOPE THROUGH

VOL. 64 ISSUE 4

MYASTHENIA GRAVIS ASSOCIATION NEWSLETTER

INSIDE THIS ISSUE

Congratulations!

Sarah Bolton 2024 Stackhouse Award Winner
Sarah, a life coach by trade, was living in California with MG when had an idea to have a virtual life coaching group in which she would work with individuals and challenge them to live a full life with MG. Four years later a plan was created to obtain a grant for the first ever Designing our Lives with MG life coaching program. In June 2024 the program set sail! Her innovation and tenacity has been an amazing addition to the MG community. She is making a difference each week as she meets with the Designing our Lives with MG crew and as our Virtual Host on our webinars. Congratulations to Sarah Bolton the 2024 Stackhouse Award Winner!

Michael Eagan 2024 Volunteer of the Year
Michael joined our Board of Directors in 2019, years after his family was impacted by myasthenia gravis through his dad's illness. He joined our Executive Committee in 2020 and became Board Chair in 2021. You've likely seen him at our events, with a smile on his face, greeting guests, lifting boxes, moving tables, putting up tents, tearing down tents quickly in the torrential rain and calculating how he can beat everybody else at Crown Town Trivia Night! He's the glue that has held us together. He challenges us to keep moving forward and making things better for our community. Congratulations Michael Eagan, our Board Chair and 2024 Volunteer of the Year!

64th Annual Meeting and Educational Seminar recap continues on page 2.

SUBMISSIONS

Want to share your MG story or have a topic you would like to see covered? Email Allison at allisonfoss@mgakc.org

FOLLOW US

@mga_heartland

@myastheniakc

https://www.facebook.com/mgakc

mgakc.org

A MESSAGE FROM ALLISON

Shifting Perspectives

Discovering the Gifts in Rare Disease

In August I had the opportunity to attend the Rare Mindset Conference put on by Patient Authentic and Amgen. Arguably one of the most impactful conferences I have ever attended with a pivotal point being the testimony of Albert Freedman, PDH on his life as a caregiver to his son with SMA. One of his points was that a rare disease may also bring rare gifts.

Then in October, as the MGA hosted it's 64th Annual Meeting & Educational Seminar, we had the opportunity to hear from Vickie Petz Kasper, MD and she shared about turning our diagnosis of myasthenia gravis into a gift.

I'm sensing a theme. Both of these sessions were lightbulb moments for me. What if we shift our mindset to the glass half full and what we have been given and how it can be used as a gift? What if we recognize that the people we have met along this journey and the ideas they share are gifts to us? What if we view the opportunity to tune into a webinar and learn about ways to improve your life through nutrition or selfcare are gifts rather than nuisances.

Life is all about perspective and how you receive the information you are given. Is there an old saying, "every day may not be good but there is good in every day?"
I am thankful for the gift of being involved in all of your lives and you in mine. For had I not been diagnosed with myasthenia gravis at age 5, I wouldn't have that gift. Nor would I have the gift of working in the space and being able to spread the message in our community on research and therapies that are forth coming.

Tis the season of gifts and if you look a little closer, you might find one is right there waiting to be opened.

With gratitude,

Allison K. Foss

Allison K. Foss | Executive Director | allisonfoss@mgakc.org

myasthenia gravis association
MGA
of the heartland

MGA STAFF
Executive Director
Allison Foss

Community Program Coordinators
Kathryn Clemens
McKenna Fulton

EXECUTIVE BOARD
President
Michael Eagan

Vice President
Brodie Beck

Secretary
Stephanie Hubers

Treasurer
Derek Haverkamp

BOARD MEMBERS
Keith Asaeli
Joe Bant
Megan Choate
Al Dimmitt
Lyndsey Fliehs
Stephanie Hubers
Graham Naasz, DDS
Mamatha Pasnoor, MD, FAAN
Ashley Steele, CMP
Tom Vansaghi, PhD

CONTACT
816-256-4100
info@mgakc.org

Myasthenia Gravis Association
64TH ANNUAL MEETING
and Educational Seminar

Highlights from the 64th Annual Meeting & Educational Seminar

The MGA's 64th Annual Meeting & Educational Seminar, held on Saturday, October 26, 2024, offered a comprehensive hybrid experience for both in-person and virtual attendees. The day began with registration at 8:30am for in-person attendees and virtual access at 9:00am., marking the MGA's commitment to inclusivity and accessibility.

President of the MGA Board of Directors, Michael Eagan, welcomed attendees and acknowledged the support from generous sponsors. Michael highlighted the program book's resources, financial updates, and new 2025 board members and officers.

Following this introduction, Executive Director Allison Foss expressed gratitude to the MGA's dedicated team, McKenna Fulton and Kathryn Clemens, as well as the board, Medical Advisory Committee, support group leaders, and sponsors. Allison's remarks centered on the importance of MGA's mission and upcoming strategic initiatives.

This year included two amazing keynotes, including a personal testimony from Dr. Vickie Petz Kasper on living with myasthenia gravis. Dr. Vickie Petz Kasper brought her personal insight and professional expertise to our meeting, drawing from her own experience living with the condition. She spoke widely on navigating the challenges of MG, emphasizing resilience and the importance of a supportive network. After a short break, Dr. Tania Papsdorf presented an update on MG treatments, dedicating time to explain the inner workings of the neuromuscular junction to help attendees gain a clearer understanding of how these newer medications work. Following her presentation, Dr. Papsdorf invited attendees to approach her with questions throughout the remainder of the event.

Highlights from the 64th Annual Meeting & Educational Seminar (continued)

Thank you to our sponsors!

ALEXION AstraZeneca Rare Disease

argenx

IMMUNOVANT

ucb

Catalyst pharmaceuticals

Johnson&Johnson

kyverna

AMGEN

Cartesian THERAPEUTICS

SUNFLOWER STATE vitalcare INFUSION SERVICES

SHOW ME STATE vitalcare

EMD SERONO

DMI PLANNERS • PRODUCERS • CREATORS

REGENERON SCIENCE TO MEDICINE

HERITAGE BIOLOGICS

In a heartwarming awards ceremony, Sarah Bolton was honored with the Stackhouse Award for her outstanding contributions and leadership in launching the "Designing our Lives with MG" life coaching program. The Volunteer of the Year award went to Board Chair Michael Eagan for his unwavering dedication and hands-on support in advancing MGA's initiatives and community impact.

As the seminar concluded, Alexion presented a special program featuring KC Pets for Life, followed by a lunch offering for networking with sponsors and exhibitors. The 64th Annual Meeting was a testament to the MGA's growth, resilience, and vision for empowering the myasthenia gravis community.

YOUR VOICE, YOUR POWER

VALUE IN POLICY

The Safe Step Act: An Essential Reform for Patient-Centered Care

The Clinical Trial Modernization Act

FDA Announces Plans for Rare Disease Innovation Hub

The Safe Step Act: An Essential Reform for Patient-Centered Care

The Safe Step Act is a piece of bipartisan legislation designed to protect patients from unnecessary delays in receiving appropriate medical treatment due to step therapy protocols. Step therapy is a practice used by insurance companies that requires patients to try less expensive treatments before gaining access to medications their doctors initially prescribed. This practice can delay access to proper care, potentially leading to worsened conditions and unnecessary suffering, especially for those with chronic illnesses like MG.

The bill proposes a streamlined process for bypassing step therapy requirements when it's medically necessary, allowing doctors to have more control in determining the best treatment for their patients. Provisions include establishing a standardized appeals process and defining clear timelines for when exceptions to step therapy must be granted, ensuring patients receive timely care.

The Safe Step Act has gained considerable traction since it was introduced in the U.S. Congress. Initially launched with the goal of making insurance protocols more patient-friendly, the bill has steadily garnered bipartisan support from lawmakers, patient advocacy groups, and healthcare providers.

Advocacy Strategies:

- Contact Your Representatives: You can call, email, or write letters urging them to cosponsor or vote in favor of a bill. Personal stories can be especially impactful.
- Share Your Story: Share your experiences on social media, in community forums, or through advocacy organizations like the MGA. Tag lawmakers and use relevant hashtags to amplify your message.
- Spread Awareness: Educate others in your community, both online and offline. The more people who understand and support a bill, the greater pressure on legislators to act.

YOUR VOICE, YOUR POWER

VALUE IN POLICY

The Clinical Trial Modernization Act

the Clinical Trial Modernization Act, is proposed legislation aimed at improving and modernizing the clinical trial process in the United States. The act is designed to address several key issues that hinder the efficiency and accessibility of clinical trials, especially for patients with rare diseases and underserved populations.

For patients with rare diseases like MG, the Clinical Trial Modernization Act represents a crucial step forward. By improving access to and inclusivity in clinical trials, it offers hope for more effective treatments tailored to the unique needs of rare disease patients. Additionally, by speeding up the trial process, patients may see new therapies brought to market more quickly.

> “We write today on behalf of Myasthenia Gravis Association patient advocacy and public health organizations to thank you for introducing H.R. 8412, the Clinical Trial Modernization Act. We are pleased to express our strong support for this important legislation, which holds great promise for improving the efficiency, inclusivity, and accessibility of clinical trials.”

Key Objectives of the Clinical Trial Modernization Act:

- Increase Diversity: Ensure that clinical trials better represent diverse populations. This is critical to making sure that trial results are applicable to a wider range of patients.
- Leverage Technology and Data: By embracing digital tools and data-driven approaches, the act seeks to make clinical trials more efficient and cost-effective.
- Expand Access: Remove barriers to clinical trial participation, particularly for patients in rural or underserved areas.
- Faster Approvals and Innovation: Promote regulatory flexibility to allow for faster approval of new therapies and innovations. This is especially important for patients with rare or life-threatening diseases, like MG.

FDA Announces Plans for Rare Disease Innovation Hub

The U.S. Food and Drug Administration (FDA) has unveiled an ambitious initiative to establish a Rare Disease Innovation Hub. This new endeavor aims to streamline the development of treatments for rare diseases, which affect a small percentage of the population but pose significant challenges due to the limited availability of effective therapies.

For the Myasthenia Gravis (MG) community, the Rare Disease Innovation Hub represents a significant step forward. MG, a rare autoimmune neuromuscular disorder, often requires specialized treatments. The hub’s focus on rare diseases means that efforts to develop new MG therapies could receive enhanced support, potentially leading to faster access to innovative treatments.

Key Objectives of the Rare Disease Innovation Hub:

- Facilitate Collaboration: The hub will serve as a central point for collaboration between researchers, pharmaceutical companies, patient advocacy groups, and other stakeholders.
- Enhance Regulatory Support: The initiative aims to provide more robust regulatory support and guidance for developers working on rare disease treatments.
- Promote Innovation: By creating a dedicated space for rare disease research and development, the FDA seeks to encourage innovation in this critical area.
- Improve Patient Outcomes: Ultimately, the hub's goal is to improve the quality of life for patients with rare diseases by ensuring that effective treatments reach the market more efficiently and safely.

Cell-Based Assay Outperforms Others for Antibody Detection in Myasthenia Gravis

A recent study highlights that cell-based assays (CBA) outperform traditional methods like radioimmunoprecipitation assay (RIPA) and enzyme-linked immunosorbent assay (ELISA) in detecting autoantibodies related to myasthenia gravis (MG). This comparison, conducted in a cohort of over 2,000 patients, showed that CBA had a higher sensitivity rate for detecting acetylcholine receptor (AChR) antibodies, reaching 72.3%, while RIPA and ELISA had lower sensitivity rates of 64.1% and 62.7%, respectively. CBA was also shown to maintain a high level of specificity, making it a more accurate and reliable first-line assay for MG diagnosis and management. This is significant because antibody detection plays a crucial role in diagnosing MG, as the disease often involves autoantibodies attacking proteins in the neuromuscular junction.

This advancement means that clinicians can better identify MG in patients, especially when AChR or muscle-specific kinase (MuSK) antibodies are difficult to detect using traditional methods. The findings underscore the importance of improving diagnostic tools to ensure more precise treatment for MG patients. By improving detection accuracy, CBAs may help diagnose more MG cases, especially in patients who previously tested negative through conventional methods. This advancement has the potential to enhance patient care by ensuring timely and precise diagnosis.

- Li Z, Zhang C, Chang T, et al; SCREAM study investigators. *A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study.* Lancet Reg Health West Pac. 2023
- *Myasthenia gravis*. Johns Hopkins Medicine.
- *Area under the curve*. Analyse-it.

Does Surgical Removal of the Thymus Have Deleterious Consequences?

Thymectomy, the surgical removal of the thymus gland, has been a long-standing treatment option for patients with myasthenia gravis (MG). The thymus plays a key role in the immune system, and abnormalities in this gland are often linked to MG. The procedure is most effective in patients with generalized MG and can lead to symptom improvement or even remission.

Recent studies have demonstrated that thymectomy can reduce the need for immunosuppressive medications and improve muscle strength in many patients. While thymectomy is not a cure, it is an important treatment consideration, especially for those who do not respond well to medication alone. The document outlines the types of thymectomy, the risks and benefits, and the latest research supporting the procedure's use in managing MG.

Kaminski HJ, Kusner LL, Cutter GR, Le Panse R, Wright CD, Perry Y, Wolfe GI. *Does Surgical Removal of the Thymus Have Deleterious Consequences?* Neurology.

Does Surgical Removal of the Thymus Have Deleterious Consequences?

Risks and Benefits

Benefits of thymectomy include:

- Reduction in Symptoms: Many patients experience fewer symptoms and a reduction in the severity of their MG after thymectomy.
- Decreased Medication Use: Studies have shown that thymectomy can reduce the need for immunosuppressive drugs, particularly corticosteroids.
- Improved Muscle Strength: Patients typically see improvements in muscle strength post-surgery, helping with day-to-day activities and quality of life.

However, risks associated with thymectomy include:

- Surgical Complications: Like any surgery, thymectomy carries risks such as infection, bleeding, and complications related to anesthesia.
- Recovery Time: Depending on the surgical approach, recovery can take several weeks, particularly for the more invasive transsternal thymectomy.
- Incomplete Symptom Resolution: While thymectomy can greatly improve symptoms, it is not a guaranteed cure, and some patients may continue to experience symptoms or require medication.

Latest Research and Support for Thymectomy

Recent clinical trials, such as the landmark MGTX study, have confirmed that thymectomy is beneficial for a broad range of MG patients, even those without thymoma. The study found that patients who underwent thymectomy alongside standard immunosuppressive therapy experienced significant improvements in symptoms, muscle strength, and reduced medication dependency compared to those who only received medical therapy. These findings have led to wider recommendations for thymectomy in MG management.

Kaminski HJ, Kusner LL, Cutter GR, Le Panse R, Wright CD, Perry Y, Wolfe GI. *Does Surgical Removal of the Thymus Have Deleterious Consequences?* Neurology.

MG CLINICAL TRIAL UPDATES

University of Kansas Medical Center

Janssen PI: Dr. Farmakidis
ClinicalTrials.gov Identifier: NCT05265273
An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children aged 2 to Less than 18 Years With Generalized Myasthenia Gravis

For more information contact: Nora Khalifa nkhalifa@kumc.edu

DAS-MG PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT04226170
A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given with Ondansetron to Subjects with anti-AchR positive Myasthenia Gravis

For more information contact: Nora Khalifa nkhalifa@kumc.edu

ALXN1720 – MG PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NTC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis.

For more information: Abby Davis adavis54@kumc.edu

KATALYST MG PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06064695
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

For more information for the KU trial location contact: Abby Davis adavis54@kumc.edu

MOM-M281-011 PI: Dr. Farmakidis ClinicalTrials.gov Identifier: NCT04951622
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis.

For more information contact: Ali Russo aciersdorff@kumc.edu

Cabaletta Bio PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT06359041

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravi

For more information: Lillian Saavedra lsaavedra2@kumc.edu

Cabaletta Bio PI: Dr. Dimachkie clinicaltrials.gov identifier: NCT05451212
A Phase 1, Open-label, Safety and Dose-finding Study of Autologous
Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor
T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis.

For more information contact: Andrew Heim aheim2@kumc.edu

WHERE IN THE WORLD IS THE MGA?

7th Annual Crown Town Trivia Night
Friday August 16 was an incredible evening and a memorable milestone for the Myasthenia Gravis Association. Your presence, support and generosity lifted us past our goal to an an amazing total of $122,000!

Rare Across America
We were excited to participate in Rare Across America hosted by Everylife Foundation for Rare Diseases over the past two weeks to share the impacts of living with rare disease.



AANEM Annual Meeting
In October Allison attended the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in Savannah, GA. While there, a member of our medical advisory committee, Dr. Ghazala Hayat, was recognized as the 2024 Distinguished Physician Award recipient for her work and achievements focused on amyotrophic lateral sclerosis (ALS) and neuromuscular disorders (NMDs).



2024 Week in Rare Summit
Attending this year’s Week in Rare, hosted by Global Genes in Kansas City on September 26th and 27th, was an inspiring and eye-opening experience. The opportunity to be part of this rare disease community was both personally and professionally meaningful.

Sunday Bingo at Craft Putt
September 22 was a great time at Craft Putt's charity bingo. What a great time together while supporting the Myasthenia Gravis Association.

EXPLORE THE POSSIBILITIES

Ask your doctor about VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) and VYVGART (efgartigamod alfa-fcab)

VYVGART® Hytrulo
(efgartigimod alfa and hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

Scan the QR code or visit VYVGART.com to learn more

Questions? Call 1-833-VYVGART (1-833-898-4278)

argenx

See You There

UPCOMING EVENTS

At the MGA

MYASTHENIA GRAVIS ASSOCIATION
TRIPLE CROWN
13th ANNIVERSARY
MAY 19, 2024

5K RUN/WALK & TOT TROT

Date: May 18, 2025
Time: 8:00am
Location: Town Center Plaza, Leawood, KS

SAVE THE DATE

Stay up to date!

Website: www.mga5k.com
Facebook: @mga5k
Instagram: @mga5k

CHICKEN N PICKLE GIVEBACK NIGHT

Date: Tuesday November 19, 2024
Time: 6:00pm - 8:00pm
Location: Chicken N Pickle | Overland Park, KS

Join us for a fun night out at Chicken N Pickle, where your meal makes a difference! 10% of all food and drink purchases will be donated directly to the Myasthenia Gravis Association. Bring friends, enjoy great food, and help us raise funds to support vital programs, resources, and community outreach for those affected by myasthenia gravis. Together, we can make an impact—one meal at a time!



HAPPY MAIL
BE PART OF THE MAGIC

What is Cards2Warriors?

Cards2Warriors sends themed cards – designed by illness warrior artists – to spread hope and encouragement to those living with long-term illness, rare disease, or disability.

During tough times, the Card Crews provide letters of support to:
- Illness Warriors
- Caregivers
- Siblings
- Medical Professionals

Join the Card Crew or sign up to receive your own Happy Mail by visiting Cards2Warriors' website.

www.cards2warriors.org

Membership Donations

Sandy and Gary Gardner
Joe Bant
Ann Mowry
Tahlula and Paul Spivy
Jimmie Harbour
Roxie Drautz
Diana Wilmoth
Eleanor Ferguson
James Dickinson
Tom Anderes
James Wadella
Dorothy Steurer

In Memoriam

William White
Robert White

SUPPORT FOR MYASTHENIA GRAVIS (MG)

MORE THAN MG

Find what makes you More Than MG

Join the community of patients, caregivers, and other advocates

Whether you're looking to hear more about MG, find a friend with the same diagnosis, or receive some motivation, there's a place for you in the More Than MG community.

Visit More Than MG to explore:

- Patient stories shared through social media
- Tips for living life beyond an MG diagnosis
- Encouraging reminders and motivation
- Resources for you and your loved ones

MoreThanMG.com ↗

Follow
@MoreThanMG

DID YOU KNOW MG CAN CAUSE DOUBLE VISION?

Visit @morethanmg for myasthenia gravis (MG) support

Use our More Than MG Instagram filter
to help spark awareness about vision impairment.

GO TO @MoreThanMG ON INSTAGRAM TAP THE SPARKLES ICON

SEE MG

SELECT THE "SEE MG" FILTER

ALEXION
AstraZeneca Rare Disease

Find A SUPPORT GROUP Near you

Missouri

Eastsiders Lunch Bunch - Blue Springs
1st Wednesday of the month | 11:30 AM - 1:00 PM | Agape House 312 SW 19th Terrace Street, Blue Springs, MO
Light lunch provided | Open to individuals, caregivers & providers
Hosted by Carol Hunt & Raymond Hankins, Volunteer Support Group Leaders
Next Meeting - November 6, 2024
RSVP to mckennafulton@mgakc.org

Kansas City Coffee Club
1st Thursday of the month | 9:30 AM - 10:30 AM | Location Varies
Coffee is Dutch treat | Open to individuals, caregivers & providers
Next Meeting – November 7, 2024
RSVP: info@mgakc.org

Greater Kansas City Support Group
Quarterly on a Saturday | 10:00 AM - 11:30 AM | St. Joseph Medical Center, Kansas City, MO
Light brunch is provided | Open to individuals, caregivers & providers
Next Meeting — December 14, 2024
RSVP: mckennafulton@mgakc.org

Kansas City Northland Support Group
January-September, bi-monthly on a Thursday | 12:00 PM - 1:30 PM | Primrose Retirement Community, 8559 N. Line Creek Road, Kansas City, MO
Light lunch is provided | Open to individuals, caregivers & providers
Hosted by Sandy Gardner, Volunteer Support Group Leader
Next Meeting – November 14, 2024
RSVP: mckennafulton@mgakc.org

Young Friends of the MGA– Kansas City
Quarterly at various locations in Kansas City | 6:00 PM - 8:00 PM
Open to individuals who are generally in their 20s, 30s and 40s
Next meeting – November 19, 2024 | Chicken N Pickle, Overland Park
RSVP: allisonfoss@mgakc.org

Find A SUPPORT GROUP Near you

Missouri

St. Joseph Support Group
Quarterly | Time TBA | Location TBA
Open to individuals, caregivers & providers
Next Meeting - November 11, 2024 | Rolling Hills Library - Belt Branch | 3:00 PM -4:30 PM
RSVP: donnasjmo@yahoo.com

Springfield Support Group
Quarterly on a Thursday | 5:30 PM - 7:00 PM | East Sunshine Church of Christ, 3721 E. Sunshine St , Springfield, MO
Open to individuals, caregivers & providers
Next Meeting – January 30, 2025
RSVP: kathrynclemens@mgakc.org

Mid-Missouri Group
Quarterly on a Thursday | 5:30 PM - 7:00 PM | Daniel Boone Regional Library, 100 W. Broadway, Columbia, MO
Open to individuals, caregivers & providers
Hosted by Jonni Sutton, Volunteer Support Group Leader
Next Meeting – February 13, 2025
RSVP: kathrynclemens@mgakc.org

St. Louis Coffee Club
4th Thursday of the month | 10:30-11:30 AM | St. Louis Bread Company, 10221 Manchester Rd, Kirkwood, MO
Coffee is Dutch treat | Open to individuals, caregivers & providers
Next Meeting – November 21, 2024
RSVP: kathrynclemens@mgakc.org

St. Louis Support Group
Quarterly on a Saturday | 10:00 AM - 11:30 AM | Glendale City Hall Auditorium, St. Louis, MO
Light brunch provided | Open to individuals, caregivers & providers
Next Meeting – January 25, 2025
RSVP: kathrynclemens@mgakc.org

Young Friends of the MGA– St. Louis
Quarterly at various locations in St. Louis | 6:00 PM - 8:00 PM |
Open to individuals who are generally in their 20s, 30s and 40s
Next Meeting – March 14, 2025
RSVP: info@mgakc.org

Find A SUPPORT GROUP Near you

Kansas

Lawrence/Topeka Area Support Group
Quarterly on a Thursday, rotates between Lawrence and Topeka, KS| 5:30 PM - 7:00 PM | Lawrence Public Library, 707 Vermont Street, Lawrence, KS & Topeka & Shawnee County Library, 1515 SW 10th Ave, Topeka, KS
Open to individuals, caregivers & providers
Next Meeting – November 21, 2024
RSVP: mckennafulton@mgakc.org

Wichita Support Group
Quarterly on a Saturday | 11:00 AM - 1:00 PM | Wichita Public Library, Alford Branch 3447 S. Meridian St. Wichita, KS
Open to individuals caregivers & providers
Hosted by Dana & Larry Paxson, Volunteer Support Group Leaders
Next Meeting – TBA
RSVP: dkptiffany@gmail.com

Arkansas

Central Arkansas Group
Quarterly on a Thursday | 5:30 PM - 7:00 PM | Fletcher Library, 823 N. Buchanan St, Little Rock, AR
Open to individuals, caregivers & providers
Hosted by Griselda Torres & Kelsey Sims, Volunteer Support Group Leaders
Next Meeting – November 7, 2024
RSVP: kathrynclemens@mgakc.org

NW Arkansas Support Group
Quarterly Saturday | 10:00 AM - 11:30 AM| Residence Inn, 4611 W Locust St Rogers, AR
Open to individuals, caregivers & providers
Next Meeting – November 9, 2024
RSVP: kathrynclemens@mgakc.org

Find A SUPPORT GROUP Near you

Virtual

Vyvgart Webinar
5:00 PM - 6:00 PM | Via Zoom
Open to individuals, caregivers & providers
Next Meeting – November 4, 2024
Register at mgakc.org

Virtual Monthly Meetup
4th Monday of the month | 6:30 PM - 7:30 PM | Via Zoom
Open to individuals, caregivers & providers
Next Meeting – November 25, 2024
Register at mgakc.org

MG Pride Group
Bi– Monthly on a Tuesday | 5:30 PM - 6:30 PM | Via Zoom
Open to individuals who identify as LGTBQ+ with MG, their allies and care partners
Hosted by Bryan Bosch, Volunteer Support Group Leader
Next Meeting – TBA
RSVP: btbosch81@gmail.com

Young Friends of the MGA– Virtual Support Group
Quarterly via zoom| 6:00 PM - 7:00 PM | Via Zoom
Open to individuals who are generally in their 20s, 30s and 40s
Next Meeting – January 27, 2025
RSVP: info@mgakc.org



Become a 2024 Member of the MYASTHENIA GRAVIS ASSOCIATION

Cut and enclose in envelope. Mail to MGA address below:

I want to support the MGA by becoming a 2024

☐	$25.00	Basic Member
☐	$64.00	64th Anniversary Member
☐	$100.00	Sustaining Member
☐	$500.00	Patron Member
☐	$1,000.00	Lifetime Member

$_______In memory of: ____________________

$_______In honor of: ____________________

Name :_________________________________

Address: _________________________________

City, State, Zip:_____________________________

Phone:_________________________________

Email: _________________________________

I am a: ☐ MG PATIENT ☐ RELATIVE ☐ FRIEND ☐ OTHER

MGA
2340 E. Meyer Blvd., Bld. 1, Suite 300A
Kansas City, MO, 64132

-Contributions may be tax deductible

-Make checks payable to:
Myasthenia Gravis Association

Myasthenia Gravis Association
2340 E. Meyer Blvd. Building 1, Suite
300A Kansas City, MO 64132
Phone: (816) 256-4100
Email: info@mgakc.org
www.mgakc.org